<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508000</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40091</org_study_id>
    <secondary_id>2010-019238-29</secondary_id>
    <nct_id>NCT01508000</nct_id>
  </id_info>
  <brief_title>Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases</brief_title>
  <acronym>BOS2</acronym>
  <official_title>Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS/NRAS Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      Patients presenting with multiple innumerable liver metastases will probably never come to
      resection, however, for all others, including patients with numerous multiple metastases or
      large metastases,resection should be considered after limited chemotherapy.

      There is consensus for a backbone chemotherapy consisting of fluoropyrimidine + oxaliplatin.
      FOLFOX was used in the previous EORTC study and is again recommended.

      The addition of targeted agents to standard chemotherapy in the perioperative strategy for
      mCRC might increase the ORR and R0 resectability, without significant increase in toxicity,
      therefore translating to a better outcome.

      It was therefore decided to design an open label, randomized, multi-center, 3-arm late phase
      II study.

      Arm A: (standard) mFOLFOX6 + Surgery Arm B: (experimental) mFOLFOX6 + Bevacizumab + Surgery
      Arm C: (experimental) mFOLFOX6 + Panitumumab + Surgery
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low or poor accrual
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Increase in progression free survival rate at 1 year in each experimental arm (mFOLFOX6 + bevacizumab or panitumumab) compared to mFOLFOX6 alone arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>4 years</time_frame>
    <description>Increase in major pathological response rate between mFOLFOX6 alone arm and each experimental arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate</measure>
    <time_frame>4 years</time_frame>
    <description>Compare the percentage of patients with total resection with these three treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>8 years</time_frame>
    <description>Overall survival is defined as the time interval between the date of randomization and the date of death. Patients who are still alive when last traced will be censored at the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>4 years</time_frame>
    <description>All adverse events will be recorded; the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Liver Metastases</condition>
  <condition>KRAS Wild Type Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: modified FOLFOX6 and Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles before and 6 cycles after surgery consisting in:
Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion
Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion
Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes
Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
On day 1 of a 14 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: modified FOLFOX6 + Bevacizumab and Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles before and 6 cycles after surgery consisting in:
Hour 0: Oxaliplatin 85 mg/m2 2-h infusion
Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion
Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion*.
Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes
Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
On day 1 of a 14 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: modified FOLFOX6 + Panitumumab and Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery
6 cycles before and 6 cycles after surgery consisting in:
Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (&gt; 1000 mg) +/- 15 min. infusion*.
Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion
Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion
Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes
Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
On day 1 of a 14 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6</intervention_name>
    <description>5-FU, folinic acid, oxaliplatin</description>
    <arm_group_label>Arm A: modified FOLFOX6 and Surgery</arm_group_label>
    <arm_group_label>Arm B: modified FOLFOX6 + Bevacizumab and Surgery</arm_group_label>
    <arm_group_label>Arm C: modified FOLFOX6 + Panitumumab and Surgery</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Targeted therapy</description>
    <arm_group_label>Arm B: modified FOLFOX6 + Bevacizumab and Surgery</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Targeted therapy</description>
    <arm_group_label>Arm C: modified FOLFOX6 + Panitumumab and Surgery</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>Arm A: modified FOLFOX6 and Surgery</arm_group_label>
    <arm_group_label>Arm B: modified FOLFOX6 + Bevacizumab and Surgery</arm_group_label>
    <arm_group_label>Arm C: modified FOLFOX6 + Panitumumab and Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven CRC with 1 to 8 metachronous or synchronous liver metastases
             considered to be completely resectable.

          -  Primary tumor (or liver metastasis) of CRC must be KRAS and NRAS status &quot;wild type&quot;.

          -  Patients must have undergone complete resection (R0) of the primary tumor at least 4
             weeks before randomization. Or for patients with synchronous metastases the primary
             tumor can be resected (R0) at the same time as the liver metastases if: the patient
             has a non-obstructive primary tumor and is able to receive preoperative chemotherapy
             (3-4 months) before surgery.

          -  Measurable hepatic disease by RECIST version 1.1.

          -  Patients must be 18 years old or older.

          -  A WHO performance status of 0 or 1. Radiotherapy alone is allowed if given pre or post
             protocol treatment.

          -  Previous adjuvant chemotherapy for primary CRC is allowed if completed at least 12
             months before inclusion in this study.

          -  All the following tests should be done within 4 weeks prior to randomization:

          -  Absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin ≥ 9 g/dL
             and white blood cell count (WBC) ≥ 3 x 109/L.

          -  Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) (to exclude severe renal
             impairment); no significant proteinuria (urine protein &lt; 1g/24 hours urine collection)
             OR urine protein/creatinine ratio &lt; 1.0 OR 1+ proteinuria on urine dipstick.

          -  Absence of major hepatic insufficiency (bilirubin ≤ 1.5 x ULN and aspartate
             aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤ 5 x ULN).

          -  Magnesium ≥ lower limit of normal (LLN)

          -  Patients with a buffer range from the normal values of +/- 5% for hematology and +/-
             10% for biochemistry are acceptable. This will not apply for Renal Function, including
             Creatinine.

          -  Women of child bearing potential (WOCBP) must have a negative serum (or urine)
             pregnancy test within 14 days prior to the first dose of study treatment.

          -  Patients of childbearing / reproductive potential should use adequate birth control
             measures, as defined by the investigator, during the study treatment period and for at
             least 6 months after the last study treatment. A highly effective method of birth
             control is defined as those which result in low failure rate (i.e. less than 1% per
             year) when used consistently and correctly.

          -  Female subjects who are breast feeding should discontinue nursing prior to the first
             dose of study treatment and until 6 months after the last study treatment.

          -  Before patient registration/randomization, written informed consent must be given
             according to ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  Evidence of extra-hepatic metastasis (of CRC).

          -  Previous chemotherapy for metastatic disease or surgical treatment (e.g. surgical
             resection or radiofrequency ablation) for liver metastasis.

          -  Previous exposure to EGFR or VEGF/VEGFR targeting therapy within the last 12 months.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks
             prior to randomization.

          -  Regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).

          -  Bleeding diathesis (e.g. hemoptysis of ≥ 1/2 teaspoon or 2.5mL), coagulopathy, or need
             for administration of full-dose anti-coagulant(s).

          -  Clinically significant cardiovascular disease, including: uncontrolled hypertension,
             New York Heart Association (NYHA) class II-IV heart failure, myocardial infarction or
             unstable angina pectoris, cerebrovascular accident or transient ischemic attack within
             the past 12 months, peripheral vascular disease ≥ grade 2, serious cardiac arrhythmia
             requiring medication and other clinically significant cardiovascular disease.

          -  Peripheral neuropathy &gt; grade 1 (Common Terminology Criteria for Adverse Events, v4.0)
             serious wound complications, ulcers, or bone fractures.

          -  Symptomatic diverticulitis or active or uncontrolled gastroduodenal ulceration.

          -  History or evidence of interstitial lung disease (e.g. pneumonitis, pulmonary
             fibrosis)

          -  Significant disease that, in the investigator's opinion, would exclude the patient
             from the study. Including known allergy or any other adverse reaction to any of the
             study drugs (including any of the excipients) or to any related compound, including
             hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant
             human or humanized antibodies.

          -  Presence of any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial.

          -  Participation in another clinical study (except sub studies of this protocol) within
             the 30 days before randomization and during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Nordlinger, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>C.H.U. AMBROISE PARE AP-HP, Boulogne-Billancourt, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephane Benoist, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>HOPITAL DE BICETRE AP-HP, Le Kremlin Bicetre, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk - Campus Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout - Campus Sint Elisabeth</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris - Hopital De Bicetre AP-HP</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint-Simon - Site Reuilly</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite (lyon)</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne - CHU de Saint-Etienne - Hopital Nord</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Privé Saint-Grégoire</name>
      <address>
        <city>Saint-Gregoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens - CHU Amiens - Hopital Sud</name>
      <address>
        <city>Salouel</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2012</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver metastases</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>KRAS wild type</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>Randomized</keyword>
  <keyword>Phase II</keyword>
  <keyword>Perioperative treatment</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Neo-adjuvant</keyword>
  <keyword>Surgery</keyword>
  <keyword>Progression Free Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

